Carl Zeiss Meditec Stock Performance
| CZMWF Stock | USD 61.22 0.00 0.00% |
The firm shows a Beta (market volatility) of -0.4, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Carl Zeiss are expected to decrease at a much lower rate. During the bear market, Carl Zeiss is likely to outperform the market. At this point, Carl Zeiss Meditec has a negative expected return of -0.14%. Please make sure to confirm Carl Zeiss' information ratio and skewness , to decide if Carl Zeiss Meditec performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Carl Zeiss Meditec has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest conflicting performance, the Stock's basic indicators remain stable and the current disturbance on Wall Street may also be a sign of long-run gains for the company stockholders. ...more
| Begin Period Cash Flow | 7.4 M | |
| Total Cashflows From Investing Activities | -148.9 M |
Carl |
Carl Zeiss Relative Risk vs. Return Landscape
If you would invest 7,000 in Carl Zeiss Meditec on August 28, 2024 and sell it today you would lose (878.00) from holding Carl Zeiss Meditec or give up 12.54% of portfolio value over 90 days. Carl Zeiss Meditec is currently producing negative expected returns and takes up 3.853% volatility of returns over 90 trading days. Put another way, 34% of traded pink sheets are less volatile than Carl, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Carl Zeiss Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Carl Zeiss' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Carl Zeiss Meditec, and traders can use it to determine the average amount a Carl Zeiss' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0375
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CZMWF |
Estimated Market Risk
| 3.85 actual daily | 34 66% of assets are more volatile |
Expected Return
| -0.14 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Carl Zeiss is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Carl Zeiss by adding Carl Zeiss to a well-diversified portfolio.
Carl Zeiss Fundamentals Growth
Carl Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Carl Zeiss, and Carl Zeiss fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Carl Pink Sheet performance.
| Return On Equity | 0.16 | |||
| Return On Asset | 0.0955 | |||
| Profit Margin | 0.15 % | |||
| Operating Margin | 0.21 % | |||
| Current Valuation | 12.07 B | |||
| Shares Outstanding | 89.44 M | |||
| Price To Earning | 75.63 X | |||
| Price To Book | 6.17 X | |||
| Price To Sales | 6.34 X | |||
| Revenue | 1.9 B | |||
| EBITDA | 419.49 M | |||
| Cash And Equivalents | 8.4 M | |||
| Cash Per Share | 0.09 X | |||
| Total Debt | 120.05 M | |||
| Debt To Equity | 0.07 % | |||
| Book Value Per Share | 22.53 X | |||
| Cash Flow From Operations | 188.2 M | |||
| Earnings Per Share | 2.93 X | |||
| Total Asset | 2.4 B | |||
| Retained Earnings | 458 M | |||
| Current Asset | 859 M | |||
| Current Liabilities | 286 M | |||
About Carl Zeiss Performance
By analyzing Carl Zeiss' fundamental ratios, stakeholders can gain valuable insights into Carl Zeiss' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Carl Zeiss has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Carl Zeiss has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, the United States, Asia, and internationally. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss operates under Medical Instruments Supplies classification in the United States and is traded on OTC Exchange. It employs 3531 people.Things to note about Carl Zeiss Meditec performance evaluation
Checking the ongoing alerts about Carl Zeiss for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Carl Zeiss Meditec help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Carl Zeiss Meditec generated a negative expected return over the last 90 days | |
| Carl Zeiss Meditec has high historical volatility and very poor performance | |
| About 59.0% of the company shares are held by company insiders |
- Analyzing Carl Zeiss' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Carl Zeiss' stock is overvalued or undervalued compared to its peers.
- Examining Carl Zeiss' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Carl Zeiss' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Carl Zeiss' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Carl Zeiss' pink sheet. These opinions can provide insight into Carl Zeiss' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Carl Pink Sheet analysis
When running Carl Zeiss' price analysis, check to measure Carl Zeiss' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Carl Zeiss is operating at the current time. Most of Carl Zeiss' value examination focuses on studying past and present price action to predict the probability of Carl Zeiss' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Carl Zeiss' price. Additionally, you may evaluate how the addition of Carl Zeiss to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |